Home » Novartis Goes Wireless for Process and Plant Info
Novartis Goes Wireless for Process and Plant Info
PharmaManufacturing.com
03/10/2010
AUSTIN, TEXAS (March 9, 2010) -- Emerson Process Management’s plant-wide wireless network is helping to improve maintenance and operator efficiency, and increase plant flexibility within the Novartis biotech production centre at Huningue, in the north east of France. Emerson’s DeltaV digital automation system with a fully integrated Wi-Fi network and mobile operator stations are providing process and plant information to operators and maintenance staff throughout the facility. The new wireless network is also improving the flexibility of the control system when there is a need to adjust a product recipe.
Novartis employs over 300 people at Huningue where they produce the active ingredient for Xolair, a drug used to treat moderate to severe persistent asthma, as well as several monoclonal antibodies and an immunosuppressant. Xolair is derived from genetically modified mammalian cells that are cultivated in a laboratory before being fermented in various bioreactors.
Localized control is essential to the efficient management of the process which is spread over three production levels, as well as being geographically dispersed. Novartis implemented a distributed architecture, based on Emerson’s DeltaV system. This has enabled operator stations to be located near the main areas of the process such as the bioreactors and tanks. To further maximize operator efficiency, Novartis recognized that they needed a control architecture that enabled their operators to be fully mobile.
Novartis is a pioneer in implementing new technology and has been using wireless since the year 2000. In 2008, when migrating to version 9 of Emerson’s DeltaV system, the company benefited from developments including integrated Wi-Fi and wireless security. In 2009, Novartis expanded the wireless architecture with additional Wi-Fi access points, implementing a complete mobile wireless solution with the DeltaV system.
"In 2000 we introduced wireless technology and recognized that it was well suited to our needs. The most recent developments to Emerson’s DeltaV system have enabled us to implement a plant wide wireless solution,” said Philippe Heitz, Head of Engineering, Novartis.
Novartis has installed a wireless network with coverage obtained on all three production levels using 10 Wi-Fi access points. The network includes 17 mobile operator stations and 100 DeltaV controllers, spread over two systems. The first system controls the upstream process of cell cultivation and harvesting. The second controls the downstream phase of purification and freezing. Both systems will soon be interconnected using Emerson’s DeltaV ZONE, a software and hardware solution for connecting two systems.
The mobile operator stations provide Novartis with complete flexibility to control its manufacturing processes. To meet the standards required for sterile zones C & D, the mobile operator stations have a stainless steel enclosure that houses the central processing unit (CPU). The devices are equipped with a USB connection to the usual keyboard, monitor and mouse for this type of environment and connect to the network of Wi-Fi access points.
Operators can move from one level to another with their mobile station and still maintain an overview of the process. This has not only significantly improved operator efficiency but it has also made it possible to reduce the number of workstations required by 50%. There have also been efficiency improvements in the area of plant maintenance. For example, by using a mobile workstation it is now possible for just one person to calibrate the instruments when previously it would have required two. Should any workstation have a fault there is no longer a need to shut down a process while the station is fixed or replaced. The flexibility offered by the wireless network and mobile workstations provides a perfect back up system. A further benefit is that when a new product is being launched or a recipe changed, the mobile stations can be moved throughout the plant as required, removing the need to install new operator stations.
"Because of the wireless network we do not need to systematically invest in new control stations, even if the production of new products requires a change to the plant equipment or layout," explained Patrick Boschert, Automation Expert, Novartis.
The benefits of the DeltaV system coupled with the wireless architecture has helped Novartis to diversify production, changing from a single-chain product, such as Xolair, to being able to produce multi-chain products such as monoclonal antibodies and immunosuppressives. This is helping Novartis meet the needs of patients.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page